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Abstract
Acute kidney injury (AKI) is common and is associated
with serious short- and long-term complications. Early
diagnosis and identification of the underlying aetiology
are essential to guide management. In this review, we
outline the current definition of AKI and the potential
pitfalls, and summarise the existing and future tools to
investigate AKI in critically ill patients.
Background
Acute kidney injury (AKI) is a syndrome characterised
by a rapid (hours to days) deterioration of kidney func-
tion. It is often diagnosed in the context of other acute
illnesses and is particularly common in critically ill pa-
tients. The clinical consequences of AKI include the ac-
cumulation of waste products, electrolytes, and fluid, but
also less obvious effects, including reduced immunity and
dysfunction of non-renal organs (organ cross-talk) [1].
The impact and prognosis of AKI vary considerably
depending on the severity, clinical setting, comorbid fac-
tors, and also geographical location. There is increasing
evidence that AKI is associated with serious short- and
long-term complications, in particular increased mortality
and morbidity, the development of chronic kidney disease
(CKD), and high financial healthcare costs. As such, AKI
is now recognized as a major public health problem [2, 3].
Rapid diagnosis and appropriate diagnostic workup are
essential to identify those types of AKI where specific
therapies and interventions are available to reverse the
injurious process within the kidneys. This review will
summarise the key aspects of diagnosis and diagnostic
work-up with particular focus on patients in the inten-
sive care unit (ICU).
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Diagnosis of AKI
The diagnosis of AKI is traditionally based on a rise in
serum creatinine and/or fall in urine output. The defin-
ition has evolved from the Risk, Injury, Failure, Loss,
End-stage (RIFLE) criteria in 2004 to the AKI Network
(AKIN) classification in 2007 [4, 5]. In 2012, both were
merged resulting in the Kidney Disease Improving Global
Outcomes (KDIGO) classification [6]. Accordingly, AKI is
diagnosed if serum creatinine increases by 0.3 mg/dl
(26.5 μmol/l) or more in 48 h or rises to at least 1.5-fold
from baseline within 7 days (Table 1). AKI stages are de-
fined by the maximum change of either serum creatinine
or urine output. The importance of both criteria was con-
firmed in a recent study in >32,000 critically ill patients
which showed that short- and long-term risk of death or
renal replacement therapy (RRT) were greatest when
patients met both criteria for AKI and when these ab-
normalities persisted for longer than 3 days [7].
Several studies in various different patient populations
have confirmed an association between stages of AKI and
short- and long-term outcomes [8–13]. However, serum
creatinine and urine output are markers of excretory func-
tion only and do not provide any information about any
other roles of the kidney, i.e. metabolic, endocrine, or im-
munological functions. They are also not kidney specific
and need to be interpreted within the clinical context.
Some patients fulfil the AKI definition but do not have
AKI, and there are also patients with clear evidence of
renal injury who do not meet the creatinine or urine cri-
teria for AKI [14, 15] (Table 2).
Limitations of creatinine-based criteria for AKI
Serum creatinine is a metabolite of creatine, a molecule
that is synthesized from the amino acids glycine and ar-
ginine in liver, pancreas, and kidneys and that serves as
a rapidly mobilizable reserve of high-energy phosphates
in skeletal muscle (Fig. 1). Creatinine production is de-
termined by the amount of creatine generated in liver,
pancreas, and kidneys, creatine ingested (i.e. intake of
red meat) and muscle function. With a molecular weight
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of 113 Da, creatinine is freely filtered by the glomeruli.
In health, it is produced at a constant rate and the rate
of production is matched by the rate of renal excretion.
However, large and sustained falls in production have
been demonstrated during critical illness [16–18].
The role of creatinine as a marker of renal function is
limited by the fact that its half-life increases from 4 h to
24–72 h if the glomerular filtration rate (GFR) decreases.
As such, the serum concentration may take 24–36 h to
rise after a definite renal insult. Furthermore, a true fall
in GFR may not be adequately reflected by serum
creatinine in patients with sepsis, liver disease, and/or
muscle wasting [15, 17, 18]. Serum creatinine concentra-
tions are also affected by drugs which compete with
tubular secretion. In this case, serum creatinine levels may
fluctuate without a change in renal function (Table 2).
There is also no standardized laboratory method for quan-
tifying serum creatinine, and substances like bilirubin or
drugs may interfere with certain analytical techniques,
more commonly with Jaffe-based assays.
Serum creatinine is measured as a concentration and
is therefore affected by variations in volume status. As a
Table 1 KDIGO definition and classification of AKI [6]
Diagnostic criteria for AKI:
AKI is defined as any of the following:
• Increase in serum creatinine by ≥0.3 mg/dl (≥26.5 μmol/l) within 48 h; or
• Increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
• Urine volume <0.5 ml/kg/h for 6 h.
AKI staging system:
AKI stage Serum creatinine criteria Urine output criteria
AKI stage I Increase of serum creatinine by ≥0.3 mg/dl (≥26.4 μmol/L) Urine output <0.5 ml/kg/h for 6–12 h
or
increase to 1.5–1.9 times from baseline
AKI stage II Increase of serum creatinine to 2.0–2.9 times from baseline Urine output <0.5 ml/kg/h for ≥12 h
AKI stage III Increase of serum creatinine ≥3.0 times from baseline Urine output <0.3 ml/kg/h for ≥24 h
or or




in patients <18 years, decrease in estimated GFR to <35 ml/min per 1.73 m2
AKI acute kidney injury, GFR glomerular filtration rate, KDIGO Kidney Disease Improving Global Outcomes, RRT renal replacement therapy
Table 2 Potential pitfalls of AKI diagnosis based on creatinine and urine criteria
Clinical scenario Consequence
Administration of drugs which interfere with tubular secretion of creatinine
(i.e. cimetidine, trimethoprim)
Misdiagnosis of AKI (rise in serum creatinine without change in
renal function)
Reduced production of creatinine (i.e. muscle wasting, liver disease, sepsis) Delayed or missed diagnosis of AKI
Ingestion of substances which lead to increased generation of creatinine
independent of renal function (i.e. creatin, cooked meat)
Misdiagnosis of AKI
Obesity Overdiagnosis of AKI if using actual weight when applying urine
output criteria
Conditions associated with physiologically increased GFR (i.e. pregnancy) Delayed diagnosis of AKI
Interference with analytical measurement of creatinine
(i.e. 5-fluorocytosine, cefoxitin, bilirubin)
Misdiagnosis and delayed diagnosis of AKI (depending on the
substance)
Fluid resuscitation and overload Delayed diagnosis of AKI (dilution of serum creatinine concentration)
Progressive CKD with gradual rise in serum creatinine Misdiagnosis of AKI
Extrinsic creatinine administration as a buffer in medications
(i.e. in dexamethasone, azasetron)
Pseudo-AKI
Oliguria due to acute temporary release of ADH (i.e. post-operatively, nausea, pain)
enhanced by maximal sodium reabsorption in the setting of volume/salt depletion
Misdiagnosis of AKI
ADH anti-diuretic hormone, AKI acute kidney injury, CKD chronic kidney disease, GFR glomerular filtration rate
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result, the diagnosis of AKI may be delayed or missed in
patients with significant fluid shifts or fluid overload
[19, 20]. This was highlighted in a post-hoc analysis of
the Fluid and Catheter Treatment Trial [20]. It revealed
that AKI was unmasked or classified differently in up
to 18 % of patients after serum creatinine levels were
adjusted for net fluid balance and estimated total body
water. Affected patients had mortality rates similar to
those with AKI that was present before adjustment.
Another important limitation of all creatinine-based
definitions of AKI is that they require a reference value
to describe “baseline” renal function. Ideally, this value
should reflect the patient’s steady-state kidney function
just before the episode of AKI. However, information on
pre-hospital kidney function is not always available so
that various surrogate estimates are frequently used.
These may include inpatient results or the imputation of
values such as back-calculating a baseline creatinine and
using an estimated glomerular filtration rate (eGFR) of
75 ml/min per 1.73 m2 in patients with missing data
[15]. Unfortunately, these methods can inflate as well as
reduce the true incidence of AKI [21–23]. At present,
there is no standard approach to determining baseline
renal function.
Creatinine-based criteria for AKI often do not take
into account underlying renal reserve. In patients with
normal kidney function, a rise in serum creatinine by
0.3 mg/dl may indeed be due to an important reduction
in GFR. In contrast, in patients with underlying CKD,
absolute rises in serum creatinine represent variable
changes in GFR, and a rise by 0.3 mg/dl may be within
the acceptable daily variation and simply reflect an in-
consequential change in GFR [24]. This is particularly
relevant when diagnosing KDIGO AKI stage 3 which is
defined by a rise in serum creatinine to >4.0 mg/dl
(≥353.6 μmol/l). A patient with a baseline serum creatin-
ine of 3.9 mg/dl (345 μmol/l) who experiences a creatinine
rise by 0.3 mg/dl in 48 h would be classified as having
KDIGO AKI stage 3, whereas such a rise would be defined
as AKI stage 1 in a patient with normal baseline renal
function [14].
Similar problems may occur when defining AKI stage
3 by the RRT criterion. The optimal timing of RRT for
AKI is not known and clinical practice is very variable.
As such, AKI staging depends directly on the decision-
making process of the clinician rather than underlying
renal function.
Finally, single serum creatinine values do not provide
any information about specific stages of the AKI process.
Importantly, they do not indicate whether a patient is
still in the progression phase or if recovery has already
begun. Also, eGFR formulae are not valid to determine
renal function in AKI.
Limitations of urine-based criteria for AKI
Urine output is an important clinical marker [7, 25] but,
like creatinine, is not renal specific. In fact, urine output
may persist until renal function almost ceases. Similarly,
oliguria may be an appropriate physiological response of
functioning kidneys during periods of prolonged fasting,
hypovolaemia, after surgery, and following stress, pain,
or trauma [26–28]. In these situations, the action of
anti-diuretic hormone (ADH) can result in the generation
of very concentrated urine with osmolarities up to 1400
mmosm/l. Assuming a daily solute load of 700 mosmoles,
the urine volume may physiologically decrease to 500 ml
(i.e. 0.28 ml/kg/h in a 70 kg person) as a result of normal
kidney function [28].
Fig. 1 Generation and clearance of creatinine. Arg arginine, Glyc glycine
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The KDIGO criteria for AKI are based on the presence
of oliguria for a minimum of 6 h [6]. Several experts
have questioned the validity of this arbitrary cut-off and
suggest using either a longer minimum period (e.g. 12 h)
or a lower threshold for urinary output (e.g. 0.3 ml/kg/h
instead of 0.5 ml/kg/h) to reach sufficient specificity for
diagnosing AKI [14, 29].
Finally, in obese patients, weight-based urine output
criteria may be particularly misleading (Table 2). In fact,
the European Renal Best Practice Guidelines (2012) rec-
ommend using the ideal weight rather than the true
weight when calculating urine output in ml/min/kg to
avoid an overdiagnosis of AKI [30].
Adjunctive diagnostic tools to diagnose AKI
In certain circumstances, it may be necessary to use add-
itional tools to diagnose AKI, especially where creatinine
and urine values change only slowly, are misleading, or
cannot be interpreted accurately. This is particularly
relevant for critically ill patients where the presence of
fluid overload, muscle wasting, sepsis, and reduced ef-
fective circulating volume may completely mask the
diagnosis of AKI.
New AKI biomarkers
Significant progress has been made in the detection and
validation of new biomarkers for AKI to replace or com-
plement serum creatinine. They vary in their anatomical
origin, physiological function, time of release after the
onset of renal injury, kinetics, and distribution [24, 25]
(Table 3, Fig. 2). In addition to diagnosing AKI earlier,
some of them may also provide information about the
underlying aetiology and indicate different stages of the
pathophysiological processes involved in AKI from acute
injury to recovery [31].
Biomarkers for AKI can be stratified into markers pri-
marily reflecting glomerular filtration (i.e. serum cystatin
C), glomerular integrity (i.e. albuminuria and proteinuria),
tubular stress (i.e. insulin-like growth factor binding protein
7 (IGFBP-7), tissue inhibitor metalloproteinase 2 (TIMP2)),
tubular damage (i.e. neutrophil gelatinase-associated lipoca-
lin (NGAL), kidney injury molecule-1 (KIM-1), N-acetyl-β-
D-glucosaminidase (NAG), liver fatty acid-binding protein
(L-FAB)), and intra-renal inflammation (i.e. interleukin-18)
[32–37] (Table 3, Fig. 2).
The availability of these new markers has allowed the
detection of subtle changes in renal function before
serum creatinine rises and the identification of patients
with evidence of kidney injury without a change in serum
creatinine, i.e. “sub-clinical AKI” [34, 35, 38–40]. Of note,
biomarker-positive, creatinine-negative patients appear to
have a greater risk of complications, a longer stay in hos-
pital and higher mortality compared to patients without a
biomarker rise [38]. However, in certain situations, these
events reflect higher severity of illness rather than degree
of AKI [41].
The 10th Acute Dialysis Quality Initiative (ADQI)
Consensus Conference proposed to utilise both function
and damage biomarkers in combination with traditional
markers of renal function to better define and characterise
AKI [35, 40] (Fig. 3). This approach appears to delineate
the spectrum of AKI better than serum creatinine and
urine output alone and has the potential to transform the
way clinicians diagnose and manage patients with AKI.
Commercial kits for measurement of cystatin C, NGAL,
IGFBP7 and TIMP-2 are available. To date, only cystatin
C is routinely used in some hospitals. Cystatin C is a low
molecular 13-kD inhibitor of lysosomal proteinases and
extracellular inhibitor of cysteine proteases. It is produced
in all nucleated cells and can be found in all tissues and
body fluids. It is freely filtered in the glomeruli and then
fully absorbed by the tubular cells and broken down. Since
there is no tubular resorption or secretion, it is considered
a better marker of GFR than serum creatinine. The main
strength is that cystatin C is less dependent on age, gender,
muscle mass, and liver function [34, 42]. However, cystatin
C levels have been reported to be altered in some patients
with cancer, thyroid dysfunction, or steroid therapy, and
smokers [43–46].
Diagnosis of acute kidney disease
AKI is defined as occurring over 7 days and CKD starts
when kidney disease has persisted for more than 90 days.
Based on epidemiological studies and histological case
series, it is clear that some patients have a slow but per-
sistent (creeping) rise in serum creatinine over days or
weeks but do not strictly fulfil the consensus criteria for
AKI [47, 48]. To classify this phase between the early
stage of AKI (first 7 days) and the onset of CKD (beyond
3 months), the KDIGO expert group proposed the term
“acute kidney disease” (AKD) and suggested the follow-
ing criteria: a GFR <60 ml/min/1.73 m2 for <3 months, a
decrease in GFR by ≥35 %, and an increase in serum cre-
atinine by >50 % for <3 months or evidence of structural
kidney damage for <3 months [6]. These criteria are cur-
rently under revision (personal communication with the
ADQI group).
Diagnostic work-up
As a syndrome, AKI can have multiple aetiologies. In
critically ill patients, the most common causes are sepsis,
heart failure, haemodynamic instability, hypovolaemia,
and exposure to nephrotoxic substances [9]. Acute par-
enchymal and glomerular renal diseases are relatively
rare. Determining the aetiology is essential to guide
management and potentially target and influence the
disease process.
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Table 3 New diagnostic biomarkers of AKI evaluated in human studies
AKI biomarker Description Handling by the kidney Factors affecting biomarker
levels
Alanine aminopeptidase (AAP) Enzymes located on the brush border
villi of the proximal tubular cells
Released from tubular brush border
after damage to proximal tubular cells
Alkaline phosphatase (ALP)
γ-Glutamyl transpeptidase (γ-GT)
Angiopoietin-1 57 kDa endothelial growth factor
secreted by endothelial cells,
including renal endothelial cells





Calprotectin Cytosolic calcium-binding complex
of two proteins of the S100 group
(S100A8/S100A9); derived from
neutrophils and monocytes;
activator of innate immune system





Chitinase 3-like protein 1 39 kDa soluble intracellular protein
of glycoside hydrolase family 18
expressed by chrondrocytes,
macrophages, endothelial cells,
neutrophils, smooth muscle, and
cancer cells;
Glomerular filtration of serum
concentrations; in addition: some
secretion by macrophages within the







Cystatin C 13 kDa cysteine protease inhibitor
produced by all nucleated human
cells and released into the plasma
at a constant rate
Freely filtered in glomeruli and
completely absorbed and
catabolized by proximal tubular cells;









α Glutathione S-transferase (α GST) 47–51 kDa cytoplasmic enzyme in
proximal tubule
Released into urine following
tubular injury
п Glutathione S-transferase (п GST) 47–51 kDa cytoplasmic enzyme in
distal tubules
Released into urine following
tubular injury
Hepatocyte growth factor (HGF) Antifibrotic cytokine produced by
mesenchymal cells and involved in
tubular cell regeneration after AKI





Hepcidin 2.78 kDa peptide hormone predominantly
produced in hepatocytes but also in
kidney, brain, and heart; regulator of iron
metabolism




Insulin-like growth factor binding
protein-7 (IGFBP-7), tissue
metalloproteinase-2 (TIMP-2)
Metalloproteinases involved in cell
cycle arrest
Released into urine after tubular
cell stress
Interleukin-18 (IL-18) 18 kDa pro-inflammatory cytokine Released into urine by proximal




Kidney Injury Molecule-1 (KIM-1) Transmembrane glycoprotein
produced by proximal tubular
cells after ischaemic or
nephrotoxic injury
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The terms “pre-renal”, “renal” and “post-renal” have
traditionally been used to narrow the differential diagno-
sis of AKI. It was a long-held view that “pre-renal AKI”
or “transient” AKI were synonymous with “hypovolaemic
AKI” and “fluid responsiveness” [49]. However, several
studies have demonstrated that tubular damage may be
present in patients with “pre-renal AKI” [50, 51]. Fur-
thermore, adverse outcomes have been noted even when
creatinine returned to baseline within 24 h [52]. Based
on these results, the ADQI group proposed to differentiate
between “functional AKI” and “kidney damage” in prefer-
ence to the terms “pre-renal”, “renal”, and “post-renal”
AKI [49].
The specific diagnostic workup in individual patients
with AKI depends on the clinical context, severity, and
duration of AKI, and also on local availability. Urinaly-
sis, examination of the urinary sediment, and imaging
studies should be performed as a minimum, with add-
itional tests depending on the clinical presentation
(Fig. 4).
Table 3 New diagnostic biomarkers of AKI evaluated in human studies (Continued)
Liver-type fatty acid-binding
protein (L-FABP)
14 kDa intracellular lipid chaperone
produced in proximal tubular
cells and hepatocytes
Freely filtered in glomeruli and
reabsorbed in proximal tubular cells;






α1 Microglobulin Low molecular weight protein
produced in liver
Freely filtered by glomeruli;
reabsorbed and catabolised by
proximal tubular cells; urinary
excretion after tubular dysfunction
Sepsis
β2 Microglobulin 12 kDa light chain of major
histocompatibility class I expressed
on cell surface of every nucleated cell
Freely filtered by glomeruli;
reabsorbed and catabolised by
proximal tubular cells; urinary










Peptide expressed in renal mesangial
cells and podocytes
Released into urine Variety of primary renal
diseases
N-acetyl-β-D-glucosaminidase (NAG) >130 kDa lysosomal enzyme; produced
in proximal and distal tubular cells
and non-renal cells
Too large to undergo glomerular





At least three different types: 25 kDa and 45 kDa NGAL undergo
glomerular filtration and reabsorption
in healthy tubular cells
Sepsis
• Monomeric 25 kDa glycoprotein
produced by neutrophils and epithelial
tissues, including renal tubular cells
• Homodimeric 45 kDa protein produced
by neutrophils
• Heterodimeric 135 kDa protein
produced by renal tubular cells
Malignancy
CKD
25 kDa and 135 kDa NGAL are released





Netrin-1 50–75 kDa laminin-related molecule,
minimally expressed in proximal tubular
epithelial cells of normal kidneys
Highly expressed in injured proximal
tubules and released into urine
Proenkephalin Endogenous polypeptide hormone in
adrenal medulla, nervous system,
immune system and renal tissue
Cleared by glomerular filtration Systemic inflammation
Pain
Retinol binding protein (RBP) 21 kDa single-chain glycoprotein;
synthesized by liver
Totally filtered by the glomeruli and
reabsorbed but not secreted by






expressed on myeloid cells-1
(sTREM-1)
Member of the immunoglobulin
superfamily of receptors expressed
on granulocytes and monocytes, also
possibly produced by endothelial cells
and tubular epithelial cells
Detectable in urine following




AKI acute kidney injury, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, GFR glomerular filtration rate, HIV human immunodeficiency virus
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Urine dipstick
Urine dipstick testing is a simple test to undertake. In
fact, the AKI guideline by the National Institute for
Health and Care Excellence (NICE) in the UK recom-
mends performing urine dipstick testing for blood, pro-
tein, leucocytes, nitrites, and glucose in all patients as
soon as AKI is suspected or detected in order not to
miss any potentially treatable glomerular or tubular
pathologies [53]. These include:
 glomerulonephritis (with haematuria and
proteinuria)
 acute pyelonephritis (with pyuria/leucocyturia and
nitrites in urine)
 interstitial nephritis (occasionally with
eosinophiluria)
It is important to consider the result of the urine dip-
stick alongside the clinical history and an evaluation of
the patient. For instance, the presence of white blood
cells is non-specific but may indicate an underlying in-
fection or acute interstitial nephritis. Similarly, dipstick
haematuria in a patient with an indwelling urinary
catheter can have multiple aetiologies ranging from
glomerulonephritis to simple trauma. Dipsticks detect
haemoglobin and remain positive even after red cell
lysis. They also detect haemoglobinuria from intravas-
cular haemolysis as well as myoglobin from muscle
breakdown. A urine dipstick positive for haemoglobin
without red blood cell positivity suggests a possible
diagnosis of rhabdomyolysis.
Urine microscopy (urinary sediment)
Urine microscopy can provide very valuable information
when performed by a skilled operator using a freshly
collected non-catheterised urine sample (Table 4). It is
not utilized very often in the ICU predominantly be-
cause it is operator dependent and requires training and
experience. When done properly, the presence of red
Fig. 2 Biomarkers of AKI. α-GST α glutathione S-transferase, AAP alanine aminopeptidase, ALP alkaline phosphatase, γ-GT γ-glutamyl transpeptidase,
п GST п glutathione S-transferase, HGF hepatocyte growth fator, IGFBP-7 insulin like growth factor binding protein 7, IL-18 interleukin 18, KIM-1
kidney injury molecule-1, L-FAB liver fatty acid-binding protein, NAG N-acetyl-β-D-glucosaminidase, NGAL neutrophil gelatinase-associated lipocalin,
RBP retinol binding protein, TIMP2 tissue inhibitor metalloproteinase 2
Fig. 3 Diagnosis of AKI based on functional and damage markers.
The combination of functional and damage biomarkers allows the
clinician to diagnose AKI earlier and to differentiate the disease
process better. It is recognised that the process is dynamic and that
patients may move from one phase to another. Reproduced with
permission from http://www.adqi.org/
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cell casts or dysmorphic red cells supports the diagnosis
of glomerular disease [54–58]. Urine microscopy may
also help to diagnose septic AKI and predict worsening
renal function. Bagshaw and colleagues collected blood
and urine samples of 83 critically ill patients with sepsis
of whom 52 % had AKI [55]. They derived a urine mi-
croscopy score based on the observed quantification of
renal tubular epithelial cells and granular casts in the
sediment and showed that septic AKI was associated
with greater urine microscopy evidence of kidney injury
compared with non-septic AKI, despite similar severity
of AKI. A higher urine microscopy score was also pre-
dictive of worsening AKI. Finally, urine microscopy can
be informative in rare cases of AKI; for instance, ethyl-
ene glycol poisoning where oxalate crystals may be seen,
in case of tumour lysis syndrome where urate crystals
may be present, or in light chain disease.
Urinary electrolytes
Measurement of urinary electrolytes and fractional ex-
cretion of sodium (FENa), urea, or uric acid has not
been consistently shown to have clear correlations with
clinical and histopathological findings [54, 59, 60]. In
situations associated with transient hypovolaemia or
hypoperfusion, healthy kidneys respond by increasing
urine osmolarity and reducing sodium and/or urea or
uric acid excretion. However, this physiological re-
sponse may be variable and confounded by CKD and
co-interventions, including diuretic therapy, aminogly-
cosides, and cardiopulmonary bypass [60–64]. Whereas
the presence of low fractional sodium (<1 %), uric acid
(<12 %), and urea excretion (<34 %) together with a
normal urinary sediment may support the diagnosis of
functional AKI, the absence of these typical urinary
electrolyte abnormalities would not exclude it [65, 66].
Finally, low FENa values have also been observed in ex-
perimental sepsis with increased renal blood flow as
well as in the first hours of sepsis in humans [67–69].
As such, the interpretation of urinary electrolytes is
challenging [70]. A single measurement of urinary elec-
trolytes has a limited role in determining the differential
diagnosis of AKI in critically ill patients. Instead, serial
monitoring of urinary electrolytes may be more useful as
sequential alterations in urine composition have been
shown to parallel the development and severity of AKI
[71, 72]. However, whether serial measurement of urine
electrolytes can also help diagnosing the aetiology of
AKI remains unclear.
Fig. 4 Diagnostic work up. AKI acute kidney injury, ANCA anti-neutrophil cytoplasmic antibody, ANA anti-nuclear antibody, Anti-ds-DNA anti-double
stranded DNA, anti-GBM anti-glomerular basement membrane, C3 complement component 3, C4 complement component 4, CK creatine kinase,
CK-MB creatine kinase MB fraction, ENA extractable nuclear antigen, HIV human immunodeficiency virus, HUS haemolytic uraemic syndrome, LDH lactate
dehydrogenase, NT-proBNP N-terminal pro-brain natriuretic peptide, TTP thrombotic thrombocytopenic purpura
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Renal ultrasound
Renal ultrasonography is useful for evaluating existing
structural renal disease and diagnosing obstruction of
the urinary collecting system. In particular, the presence
of reduced corticomedullary differentiation and decreased
kidney size is indicative of underlying CKD. In patients
with abdominal distension ultrasonography can be tech-
nically challenging, in which case other imaging studies
will be necessary.
Renal Doppler ultrasound and contrast-enhanced ultra-
sound are two relatively new techniques that may be used
at the bedside to estimate renal perfusion and renal
cortical microcirculation, respectively [73–75]. The
non-invasiveness, repeatability, and accessibility of these
techniques appear promising, but broad clinical use is still
limited by training requirements as well as uncertainty
how to interpret the information obtained. Finally, al-
though Doppler scans may detect the presence of reduced
renal blood flow, they are of little use to determine the
specific aetiology of AKI.
Measurement of intra-abdominal pressure
In case of suspected AKI due to intra-abdominal compart-
ment syndrome, serial measurement of intra-abdominal
pressure should be considered. Those with a pressure rise

















can also be seen if urine
sample is not fresh at
time of microscopy
Red cell casts Diagnostic of glomerular
disease
Leukocytes Up to 3 per high-power




White cell casts Renal infection
Hyaline casts Any type of renal disease
Table 4 Interpretation of urine microscopy findings (Continued)








Crystals Some crystals can be




Bacteria Urinary tract infection;
contamination
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to >20 mmHg should be suspected of having AKI as a re-
sult of intra-abdominal compartment syndrome [76].
Autoimmune profile
Depending on the clinical context, clinical signs, and
urine dipstick results, patients may require specific im-
munological tests, including anti-neutrophil cytoplasmic
antibody (ANCA), anti-nuclear antibody (ANA), anti-
glomerular basement membrane antibody (anti-GBM),
and complement component 3 and 4 to rule out im-
mune-mediated diseases (i.e. vasculitis, connective tis-
sue diseases) (Fig. 4). These investigations should be
considered mandatory in patients with AKI presenting
primarily with a pulmonary-renal syndrome, haemopty-
sis, or haemolysis/thrombocytopenia.
Renal biopsy
Renal biopsies are rarely performed in critically ill pa-
tients, mainly due to the perceived risk of bleeding com-
plications and general lack of therapeutic consequences.
However, a renal biopsy may offer information that is
not available through other means and should be con-
sidered if underlying parenchymal or glomerular renal
disease is suspected (Fig. 4). Interestingly, Chu et al. re-
ported that diffuse histological changes of AKI could be
present without a sufficient change in serum creatinine
[47]. Among 303 patients with biopsy-proven acute
parenchymal renal lesions, including crescentic glomer-
ulonephritis and acute thrombotic microangiopathy,
only 198 patients (65 %) met the KDIGO creatinine or
urine criteria for AKI. In a separate study from France,
about 50 % of patients with AKI undergoing renal biopsy
had a diagnosis distinct from acute tubular necrosis that
frequently resulted in a change of treatment regimen
[77]. Recent reports have suggested that transjugular
renal biopsies may be safer than percutaneous or open
techniques [78].
Other laboratory tests
Depending on the clinical context, the following tests
may be indicated:
 serum creatine kinase and myoglobin (in case of
suspected rhabdomyolysis)
 lactate dehydrogenase (LDH) (in case of suspected
thrombotic thrombocytopenic purpura (TTP))
 fragmentocytes (in case of possible TTP/haemolytic
uraemic syndrome (HUS))
 N-terminal pro-brain natriuretic peptide (NT-proBNP)
and troponin (in case of suspected cardio-renal
syndrome)
 serum/urine protein electrophoresis (in case of
suspected myeloma kidney)
Challenges of diagnosing AKI in critically ill patients
As outlined earlier, the use of serum creatinine to estimate
GFR in critically ill patients is limited by the lack of
steady-state conditions, unpredictable rate of production,
and variable degree of elimination (Table 2). Medications
may cause increases in creatinine without reflecting a true
decrease in GFR and fluid overload may lead to a dilution
of creatinine concentrations. Finally, serum creatinine sub-
stantially lags behind a reduction in GFR and thus does
not provide a useful real-time assessment of GFR. It is
therefore not surprising that AKI is often diagnosed late in
critically ill patients.
The interpretation of additional diagnostic investiga-
tions can be challenging, too. Dipstick haematuria is not
uncommon in patients with an indwelling urinary catheter
and most commonly due to simple trauma. Even more
specialised tests, like autoimmune tests, have a higher risk
of false-positive results in critically ill patients. For in-
stance, infection is a frequent cause of a false-positive
ANCA result [79]. Until more reliable tests are routinely
used in clinical practice it is essential to interpret creatin-
ine results and other diagnostic tests within the clinical
context [80].
Future diagnostic tools
A variety of new functional and damage markers of AKI
have been shown to provide information related to the
underlying pathophysiology of AKI and may also be uti-
lised as diagnostic tools. It is expected that some of
these markers will be routinely integrated into the defin-
ition as well as diagnostic workup of AKI [49].
Achieving the ability to rapidly and accurately measure
and monitor GFR in real time would be very beneficial,
especially in the ICU [81, 82]. Several groups are devel-
oping optical measurement techniques using minimally
invasive or non-invasive techniques that can quantify
renal function independent of serum creatinine or urine
output. In the past few years, significant progress has
been made in using two-photon excitation fluorescence
microscopy to study kidney function [82]. It is very likely
that several of these approaches will enter clinical phase
studies in the very near future. These techniques will enable
an earlier diagnosis of AKI and also provide opportunities
to improve clinical management, including the use of
nephrotoxic substances and appropriate drug dosing.
New imaging techniques may also be utilised, including
cine phase-contrast magnetic resonance imaging or intra-
vital multiphoton studies [83, 84]. However, given the
complexity, financial costs, and need for patient transport,
it is likely that they will remain research tools.
Conclusion
Acute kidney injury is a clinical syndrome defined by a
rise in serum creatinine and/or fall in urine output as
Ostermann and Joannidis Critical Care  (2016) 20:299 Page 10 of 13
per KDIGO classification. Future definitions are likely to
incorporate novel functional and damage biomarkers to
characterise AKI better. Early diagnosis and appropriate
diagnostic work-up are essential to determine the under-
lying aetiology and to identify cases of AKI that require
specific and timely therapeutic interventions. The exact
diagnostic investigations depend on the clinical context
and should include routine baseline tests as well as more
specific and novel tools.
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